{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiben4ou4him3vi44c7ub4vt2jguva4yx7xcytyqg4manekmjzhvra",
    "uri": "at://did:plc:ao3t7cr3n5vz5lhwlje3oied/app.bsky.feed.post/3mihgfsr2vzs2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreidq3j2qcltq5imqu545xo76wcgaqf7lsaiv6vxmsrwlu2k7bjgcga"
    },
    "mimeType": "image/jpeg",
    "size": 101153
  },
  "path": "/story/fda-approves-eli-lillys-glp-1-pill/",
  "publishedAt": "2026-04-01T18:56:03.000Z",
  "site": "https://www.wired.com",
  "tags": [
    "Science",
    "Science / Health",
    "medicine",
    "pharmaceutical industry",
    "science",
    "GLP-1",
    "Weight Loss"
  ],
  "textContent": "Eli Lilly’s once-daily Foundayo is the second obesity pill to receive FDA approval. It will compete with Novo Nordisk’s pill version of Wegovy.",
  "title": "FDA Approves Eli Lilly’s GLP-1 Pill"
}